Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrobuvir + danoprevir/ritonavir + ribavirin with or without mericitabine in treatment-naive hepatitis C genotype 1
2012-000638-21Phase 2Completed
- Sponsor
- Roche
- Start
- May 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine in chronic hepatitis C virus infection (4 arms), sponsored by Roche. Primary endpoint: Sustained virologic response. Started May 2012; status: completed.
02
Drugs
setrobuvirdanoprevirritonavirribavirinmericitabine
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2012-000638-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000638-21.